FDA-cleared Alzheimer’s blood tests are intended for adults who already have signs, symptoms, or complaints of cognitive decline—not for symptom-free people seeking routine screening. As of July 25, 2026, two tests have been cleared, with different intended uses: Fujirebio’s Lumipulse test is for adults 50 and older evaluated in specialized care, while Roche’s Elecsys test is for adults 55 and older during the initial assessment of Alzheimer’s disease and other possible causes of cognitive decline. For example, a 67-year-old experiencing worsening memory, repeated questions, and difficulty managing bills might be an appropriate candidate after a clinician evaluates the symptoms. A healthy 45-year-old who wants to learn whether Alzheimer’s could develop decades later would not fit either test’s FDA-cleared population.
Neither test is a general wellness check, a direct-to-consumer risk forecast, or a stand-alone Alzheimer’s diagnosis. The distinction matters because “the FDA-cleared Alzheimer’s blood test” is no longer a singular category. The FDA cleared Fujirebio’s test in May 2025 and Roche’s in October 2025. Both are prescription in-vitro diagnostic tests, but they measure different biomarkers and are meant to answer different clinical questions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check FDA-cleared Lumipulse eligibility and limits — Verify that Lumipulse is for adults 50+ with cognitive-decline symptoms in specialized care, not routine screening.
- Check FDA-cleared Elecsys initial-assessment use — Verify that Elecsys is for adults 55+ with cognitive concerns during initial assessment and not for patients already referred to a specialist.
Table of Contents
- Who Are the FDA-Cleared Alzheimer’s Blood Tests Intended For?
- How the Lumipulse Alzheimer’s Blood Test Is Used
- What the FDA-Reviewed Lumipulse Study Found
- What Patients and Families Should Ask Before Testing
- False Results, Recall Concerns, and Other Limitations
- How Roche’s Elecsys Test Fits Into an Initial Assessment
- Who Should Not Use These Tests as Routine Screening?
- Frequently Asked Questions
Who Are the FDA-Cleared Alzheimer’s Blood Tests Intended For?
Fujirebio’s lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio is intended for adults 50 and older who have signs and symptoms of cognitive decline and present in a specialized-care setting. Its purpose is to help clinicians identify amyloid pathology associated with Alzheimer’s disease. The FDA cleared it on May 16, 2025, through the Class II 510(k) substantial-equivalence pathway under K242706; it was not granted drug-style FDA approval. FDA 510(k) database The age threshold requires careful reporting. The FDA’s May 2025 press release described the intended population as adults 55 and older, but the controlling decision summary and indications-for-use labeling specify adults 50 and older.
The cleared labeling is therefore the more authoritative source for clinical use. FDA decision summary FDA press release Roche’s Elecsys Phospho-Tau (181P) Plasma test serves a somewhat different population and stage of care. It is intended for adults 55 and older with signs, symptoms, or complaints of cognitive decline, helping with the initial assessment of Alzheimer’s disease and other causes of decline. A 59-year-old who tells a primary-care clinician about persistent memory problems may fit the Elecsys indication, whereas the Lumipulse labeling places its use in specialized care. FDA decision summary, K252163.
How the Lumipulse Alzheimer’s Blood Test Is Used
Lumipulse is a prescription laboratory test performed on K2-EDTA plasma. It measures phosphorylated tau 217, or pTau217, and beta-amyloid 1-42, then combines the measurements into a ratio using the Lumipulse G1200 system. The component measurements are not intended to be interpreted individually. This differs from Roche’s Elecsys test, which measures plasma pTau181 on cobas e analyzers. The ratio produces three possible categories. A result at or below 0.00370 is negative and consistent with amyloid pathology being unlikely.
A result at or above 0.00738 is positive and consistent with amyloid pathology being likely. Values from 0.00371 through 0.00737 are indeterminate, prompting consideration of additional testing. These categories concern amyloid pathology; they do not independently establish that Alzheimer’s disease is causing a person’s symptoms. FDA decision summary, K242706 That limitation is important in real clinical practice. A patient can have amyloid plaques without those plaques fully explaining the cognitive problem, while symptoms may instead arise from vascular disease, Lewy body disease, medication effects, depression, sleep disorders, thyroid problems, vitamin deficiencies, or several conditions at once. A positive blood result should therefore be interpreted with the medical history, cognitive evaluation, neurological examination, laboratory work, imaging, and other relevant information.
What the FDA-Reviewed Lumipulse Study Found
The FDA-reviewed Lumipulse study included 499 cognitively impaired participants. Of that group, 58.1% had Alzheimer’s disease, 30.9% had mild cognitive impairment, 9.8% had subjective cognitive decline, and 1.2% had other diagnoses. The test’s blood-based classifications were compared with amyloid positron emission tomography or cerebrospinal-fluid results. FDA decision summary, K242706 According to the FDA, 91.7% of positive blood-test results aligned with amyloid-positive PET or cerebrospinal-fluid findings, while 97.3% of negative results aligned with amyloid-negative PET or cerebrospinal-fluid findings.
However, 19.6% of participants received an indeterminate result. That means roughly one in five study participants did not get a clear positive or negative classification from the blood test. FDA press release Consider a person whose result falls in the indeterminate range after a specialist has documented progressive cognitive impairment. The blood draw may still contribute useful information, but it may not prevent the need for an amyloid PET scan or lumbar puncture. The practical advantage of a blood test—being less invasive and generally easier to obtain—must be weighed against the possibility that it will leave the central question unresolved.
What Patients and Families Should Ask Before Testing
Before testing, patients and care partners should ask which FDA-cleared test is being ordered, why it fits the person’s age and clinical situation, and how the result could change the next step. They should also ask whether the laboratory is using the test within its cleared indication. A test ordered for a symptomatic 72-year-old in a memory clinic is a different use case from screening an asymptomatic person because a parent had Alzheimer’s disease. It is also worth discussing the plan for every possible result.
A clinician might use a negative result to investigate non-Alzheimer’s explanations more closely, while a positive result could lead to confirmatory testing or inform decisions about therapies that require evidence of amyloid pathology. An indeterminate Lumipulse result may lead to PET imaging or cerebrospinal-fluid analysis, so the blood test can reduce—but does not always eliminate—the need for more expensive or invasive procedures. Patients should clarify what “positive” means before receiving the report. It means that amyloid pathology is likely under the test’s interpretation criteria, not that the person unquestionably has Alzheimer’s dementia. The conversation should also cover how results will be communicated, whether a care partner should attend, and what clinical support is available if the findings cause distress.
False Results, Recall Concerns, and Other Limitations
The FDA identifies false-positive and false-negative results as the principal safety risks of Lumipulse. A false positive can contribute to an inappropriate diagnosis or treatment, psychological distress, treatment side effects, added costs, and delayed recognition of the true cause of cognitive decline. A false negative can also delay effective treatment and may lead to other unnecessary diagnostic procedures. FDA press release There is also material current safety context: Fujirebio initiated a Class II recall on December 11, 2025, and the FDA posted the recall on February 5, 2026. The recall concerns certain controls and reagents that could produce falsely elevated positive or indeterminate results and reduce specificity.
The recall remains open as of July 25, 2026. It does not establish that every Lumipulse result is invalid, but clinicians and laboratories should determine whether affected materials were involved when evaluating a result. FDA recall record A patient who received a positive or indeterminate Lumipulse result should not assume the recall automatically changes the diagnosis. A practical response is to contact the ordering clinician or laboratory with the test date and report, ask whether the relevant reagent or control lot was affected, and discuss whether reinterpretation, repeat testing, or confirmation through another method is warranted. Treatment should not be started, stopped, or changed solely on the patient’s interpretation of a recall notice.
How Roche’s Elecsys Test Fits Into an Initial Assessment
The FDA cleared Roche’s Elecsys Phospho-Tau (181P) Plasma test on October 8, 2025, under K252163. It is a prescription-only test for adults 55 and older who have signs, symptoms, or complaints of cognitive decline.
It measures pTau181 in plasma on cobas e analyzers and is intended to aid the initial assessment of Alzheimer’s disease and other causes of cognitive decline. FDA 510(k) database For example, a clinician beginning the workup of a 76-year-old with new memory complaints might consider Elecsys as one element of the initial assessment, alongside medication review, cognitive testing, physical examination, and laboratory studies. Its clearance does not turn a pTau181 result into a complete diagnosis, and it should not replace evaluation for reversible or competing causes of cognitive symptoms.
Who Should Not Use These Tests as Routine Screening?
Neither FDA-cleared test is intended as population-wide screening for people without cognitive symptoms. Someone with normal cognition who is worried because of age, family history, or an APOE genetic result does not automatically fall within the cleared indication. The same is true of a younger adult seeking reassurance after occasionally forgetting names during a stressful period.
FDA clearance also does not make these tests do-it-yourself tools. Both require a prescription and professional interpretation in the context of a clinical assessment. For Lumipulse specifically, the labeling states that a positive result does not establish a diagnosis of Alzheimer’s disease or any other cognitive disorder, and its cleared population consists of symptomatic adults 50 and older presenting in specialized care.
Frequently Asked Questions
Has the FDA approved an Alzheimer’s blood test?
The FDA has cleared two Alzheimer’s-related blood tests as medical devices through the 510(k) pathway. “FDA-cleared” is the accurate term; this is not the same as drug-style FDA approval.
Can a healthy person request one as an Alzheimer’s screening test?
The cleared indications do not cover routine screening of symptom-free people. Both tests are intended for adults with signs, symptoms, or complaints of cognitive decline.
Does a positive Lumipulse result confirm Alzheimer’s disease?
No. It indicates that amyloid pathology is likely under the test’s criteria. The result must be considered with clinical information and does not independently diagnose Alzheimer’s disease or another cognitive disorder.
What happens after an indeterminate Lumipulse result?
The clinician may consider further evaluation, including amyloid PET imaging or cerebrospinal-fluid testing. In the FDA-reviewed study, 19.6% of participants had indeterminate results.
Are Lumipulse and Elecsys interchangeable?
No. Lumipulse combines pTau217 and beta-amyloid 1-42 into a ratio for symptomatic adults 50 and older in specialized care. Elecsys measures pTau181 and aids the initial assessment of symptomatic adults 55 and older.
What should someone do if a Lumipulse test may have involved recalled materials?
Contact the ordering clinician or testing laboratory, provide the test date and report, and ask whether an affected reagent or control lot was used. The answer can guide decisions about reinterpretation, repeat testing, or confirmation.
